( 您好!臺灣時間:2021/08/05 10:19
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Ying-Han Wang
論文名稱(外文):The Anti-tumor Mechanism of Combine Destruxin B with Iressa in Human Lung Cancer Cells
指導教授(外文):Chien-Ho ChenCheng-Ming Liu
外文關鍵詞:NSCLCK-ras mutaionafter
  • 被引用被引用:0
  • 點閱點閱:158
  • 評分評分:
  • 下載下載:48
  • 收藏至我的研究室書目清單書目收藏:0
全球因癌症死亡的案例中,肺癌首居其位,而肺癌引發的死亡率遠超過前列腺癌、乳癌以及結腸直腸癌等。先前研究指出有許多治療標的針對癌細胞的生長及存活,其一標的為表皮生長因子接受器(Epidermal growth factor receptor, EGFR),在許多癌症如頭頸癌、乳癌及咽喉癌可見表皮生長因子接受器(Epidermal growth factor receptor, EGFR)有過度表現的情形,愛瑞莎(Iressa)即為一種口服的表皮生長因子接受器酪胺酸激酶抑制劑(EGFR-TKI)。但服用愛瑞莎受限於劑量及其所產生的副作用。黑殭菌素(Destruxins)為黑殭菌(Metarrhizium anisopliae)二次代謝物,為環狀胜肽物質(cyclic hexadepsipeptides)。先前研究指出,在人類肝癌細胞黑殭菌素B (Destruxin B)對於B型肝炎病毒表面抗原(HBsAg)之基因表現具抑制效果。故本實驗目的合併使用Iressa與黑殭菌素B(Destruxin B),觀察對於A549肺腺癌(EGFR wild type, K-ras mutaion)、FaDu鱗狀上皮肺癌(EGFR wild type, K-ras wild type)細胞株,探討合併藥物的抗腫瘤機制。依文獻K-ras突變時使用Iressa (EGFR inhibitor)並不具有反應,本實驗用流式細胞儀分析及粒線體膜電位發現愛瑞莎(7μM)對A549肺腺癌(K-ras mutation)效果較差,符合先前文獻;但在Destruxin B合併使用愛瑞莎反而發現A549肺腺癌具有良好的反應,此結果顯示Destruxin B待未來通過臨床檢測之後,對於肺腺癌(Adenocarcinoma,尤其具K-ras mutation)的治療,可能使得治療肺癌更具專一性。此外,依西方墨點法分析,可知A549細胞透過外在路徑與內在路徑造成細胞凋亡,以及AIF的釋放使細胞走向凋亡,即不需由caspase活化之caspase-independent pathway;而FaDu細胞則是透過外在路徑造成細胞凋亡。
Lung cancer is the leading cause of cancer deaths worldwide, representing more deaths than those from prostate, breast, and colorectal cancers combined. Recent development in cancer biology have identified many therapeutic target drugs, one of these target drugs is Iressa(Gefitinib), is an orally active EGFR tyrosine kinase (EGFR-TKI) for NSCLC therapy. But efficacy to Iressa is limited to dosage and side effect. Recent studies indicate that Destruxin B is a second metabolite of fungus (Metarhizium anisopliae) In human, Destruxin B could inhibit Hepatitis B surface antigen(HBsAg) gene expression in Hep3B cell. The aim to this report is combine DB and Iressa to treat human adenocarcinoma cell (A549,K-ras mutation) and human squamous cell (FaDu,K-ras wt), to observe the anti-tumor efficacy. Previous studies indicate that Iressa treatment has resistant to NSCLC patients with K-ras mutation, this corresponds to our results in Flow cytometry. However, combined therapy seemed to be good response in A549 adenocarcinoma, suggests that Destruxin B may be a potential drug in lung cancer therapy after passing clinical trials, particularly in adenocarcinoma cells with K-ras mutaion expression. In other hand, we observed the signal pathway of combined drugs by western blotting, showed that A549 cells induced apoptosis via extrinsic and intrinsic pathway; and release of AIF protein resulting in cells apoptosis via caspase-independent pathway without caspase activation. FaDu cells induced apoptosis via extrinsic pathway.
第一章 緒論 1
一、 研究目的 1
二、 肺癌簡介 2
三、細胞凋亡簡介 4
四、Iressa(Gefitinib)愛瑞莎簡介 6
五、黑殭菌素(Destruxins)簡介 6
六、粒腺體膜電位( Mitochondrial membrane potential ) 6
第二章 實驗材料與方法 6
一、藥品試劑 6
二、常用溶液 6
三、黑殭菌素的取得 6
四、Gefitinib的取得 6
五、細胞培養 6
六、細胞存活率計算 6
七、流式細胞儀分析 6
八、粒腺體膜電位( Mitochondrial membrane potential ) 6
九、西方墨點法( Western blotting assay ) 6
十、統計方式 6
第三章 結果 6
一、黑殭菌素B(Destruxin B)合併愛瑞莎(Iressa)對於肺癌細胞株的細胞生長之影響 6
二、黑殭菌素B(Destruxin B)合併愛瑞莎(Iressa)誘導人類肺癌細胞株之細胞凋亡 6
三、黑殭菌素B(Destruxin B)合併愛瑞莎(Iressa) 作用誘使人類肺腺癌A549及人類鱗狀上皮肺癌細胞FaDu粒線體膜電位表現 6
四、黑殭菌素B(Destruxin B)合併愛瑞莎(Iressa)作用誘導人類肺腺癌A549凋亡相關蛋白的表現 6
五、黑殭菌素B(Destruxin B)合併愛瑞莎(Iressa)作用誘導人類鱗狀上皮肺癌細胞FaDu凋亡相關蛋白的表現 6
第四章 討論 6
第六章 圖表 6
第七章 參考文獻 6
陳拯裕 (2006) 黑殭菌素B對人類大腸癌及肝癌細胞株之抗癌機制與探討。朝陽科技大學生物技術研究所論文。
黎培琪 (2004) 黑殭菌素(Destruxin B)對DBA/2老鼠L5178Y淋巴癌細胞之抑制效果及其機制。私立台北醫學大學生物醫學技術研究所碩士論文。
Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996). Human ICE/CED-3 protease nomenclature. Cell 87, 171.
Arends, M. J., Morris, R. G., and Wyllie, A. H. (1990). Apoptosis. The role of the endonuclease. Am J Pathol 136, 593-608.
Arnoult, D., Gaume, B., Karbowski, M., Sharpe, J. C., Cecconi, F., and Youle, R. J. (2003). Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. Embo J 22, 4385-4399.
Birnbaum, A., and Ready, N. (2005). Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol 6, 75-81.
Bortner, C. D., and Cidlowski, J. A. (2002). Apoptotic volume decrease and the incredible shrinking cell. Cell Death Differ 9, 1307-1310.
Brenner, C., and Kroemer, G. (2000). Apoptosis. Mitochondria--the death signal integrators. Science 289, 1150-1151.
Cai, P., Smith, D., Katz, B., Pearce, C., Venables, D., and Houck, D. (1998). Destruxin-A4 chlorohydrin, a novel destruxin from fungus OS-F68576: isolation, structure determination, and biological activity as an inducer of erythropoietin. J Nat Prod 61, 290-293.
Cande, C., Vahsen, N., Garrido, C., and Kroemer, G. (2004). Apoptosis-inducing factor (AIF): caspase-independent after all. Cell Death Differ 11, 591-595.
Castedo, M., Hirsch, T., Susin, S. A., Zamzami, N., Marchetti, P., Macho, A., and Kroemer, G. (1996). Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. J Immunol 157, 512-521.
Chen, H. C., Chou, C. K., Sun, C. M., and Yeh, S. F. (1997). Suppressive effects of destruxin B on hepatitis B virus surface antigen gene expression in human hepatoma cells. Antiviral Res 34, 137-144.
Chen, L. B. (1988). Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4, 155-181.
Clement, M. V., Hirpara, J. L., and Pervaiz, S. (2003). Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 10, 1273-1285.
Cohen, G. M. (1997). Caspases: the executioners of apoptosis. Biochem J 326 ( Pt 1), 1-16.
Earnshaw, W. C., Martins, L. M., and Kaufmann, S. H. (1999). Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68, 383-424.
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Janne, P. A., Januario, T., Johnson, D. H., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23, 5900-5909.
Heerdt, B. G., Houston, M. A., Anthony, G. M., and Augenlicht, L. H. (1998). Mitochondrial membrane potential (delta psi(mt)) in the coordination of p53-independent proliferation and apoptosis pathways in human colonic carcinoma cells. Cancer Res 58, 2869-2875.
Heerdt, B. G., Houston, M. A., Mariadason, J. M., and Augenlicht, L. H. (2000). Dissociation of staurosporine-induced apoptosis from G2-M arrest in SW620 human colonic carcinoma cells: initiation of the apoptotic cascade is associated with elevation of the mitochondrial membrane potential (deltapsim). Cancer Res 60, 6704-6713.
Hengartner, M. O., and Bryant, J. A. (2000). Apoptotic cell death: from worms to wombats ... but what about the weeds? Symp Soc Exp Biol 52, 1-12.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., and Thun, M. J. (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
Kirkin, V., Joos, S., and Zornig, M. (2004). The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 1644, 229-249.
Kok, J. W., and Sietsma, H. (2004). Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 5, 375-382.
Kuwana, T., and Newmeyer, D. D. (2003). Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol 15, 691-699.
Linder, S., Havelka, A. M., Ueno, T., and Shoshan, M. C. (2004). Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 214, 1-9.
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
Manning, A. S. (1988). Reperfusion-induced arrhythmias: do free radicals play a critical role? Free Radic Biol Med 4, 305-316.
Morel, E., Pais, M., Turpin, M., and Guyot, M. (1983). Cytotoxicity of cyclodepsipeptides on murine lymphocytes and on L 1210 leukemia cells. Biomed Pharmacother 37, 184-185.
Muroi, M., Shiragami, N., and Takatsuki, A. (1994). Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun 205, 1358-1365.
Nicholson, R. I., Gee, J. M., and Harper, M. E. (2001). EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4, S9-15.
O'Flaherty, J., Mei, Y., Freer, M., and Weyman, C. M. (2006). Signaling through the TRAIL receptor DR5/FADD pathway plays a role in the apoptosis associated with skeletal myoblast differentiation. Apoptosis 11, 2103-2113.
Orrenius, S. (2004). Mitochondrial regulation of apoptotic cell death. Toxicol Lett 149, 19-23.
Pao, W., Miller, V. A., and Kris, M. G. (2004). 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol 14, 33-40.
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., and Varmus, H. E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2, e17.
Pedras, M. S., Irina Zaharia, L., and Ward, D. E. (2002). The destruxins: synthesis, biosynthesis, biotransformation, and biological activity. Phytochemistry 59, 579-596.
Petit, P. X., Susin, S. A., Zamzami, N., Mignotte, B., and Kroemer, G. (1996). Mitochondria and programmed cell death: back to the future. FEBS Lett 396, 7-13.
Saraste, A., and Pulkki, K. (2000). Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45, 528-537.
Schwartzman, R. A., and Cidlowski, J. A. (1993). Mechanism of tissue-specific induction of internucleosomal deoxyribonucleic acid cleavage activity and apoptosis by glucocorticoids. Endocrinology 133, 591-599.
Stennicke, H. R., and Salvesen, G. S. (1998). Properties of the caspases. Biochim Biophys Acta 1387, 17-31.
Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., et al. (1999). Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397, 441-446.
Thorburn, A. (2004). Death receptor-induced cell killing. Cell Signal 16, 139-144.
Tsunoo, A., Kamijo, M., Taketomo, N., Sato, Y., and Ajisaka, K. (1997). Roseocardin, a novel cardiotonic cyclodepsipeptide from Trichothecium roseum TT103. J Antibiot (Tokyo) 50, 1007-1013.
Vansteenkiste, J. (2004). Gefitinib (Iressa): a novel treatment for non-small cell lung cancer. Expert Rev Anticancer Ther 4, 5-17.
第一頁 上一頁 下一頁 最後一頁 top